



## In the Claims

The Examiner is requested to re-write the claims as follows, without prejudice to the filing of future continuing applications.

1. (ORIGINAL) A compound represented by Formula (I):



wherein R is a cyclic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; X is a bond or a divalent chain hydrocarbon group which may be substituted; X' is a bond or -N(R<sup>5</sup>)- (wherein R<sup>5</sup> is a hydrogen atom, a hydrocarbon group which may be substituted, an esterified or amidated carboxyl group, or an acyl group); Y is a divalent hydrocarbon group which may be substituted; Y' is a bond or -C(=O)-; ring A is a nitrogen-containing heterocycle which may be substituted; Z<sup>1</sup> and Z<sup>3</sup> are each independently a bond or a divalent chain hydrocarbon group which may be substituted; Z<sup>2</sup> is a bond or -N(R<sup>6</sup>)- (wherein R<sup>6</sup> is a hydrogen atom, a hydrocarbon group which may be substituted, or an acyl group); B is a group represented by the formula:




(wherein  $R^1$  and  $R^2$  are each independently a hydrogen atom, a halogen atom, a hydrocarbon group which may be substituted, an alkoxy group which may be substituted, a carboxyl group which may be esterified or amidated, an acyl group, or an amino group which may be substituted;  $R^3$  is a hydrogen atom, a hydrocarbon group which may be substituted, a carboxyl group which may be esterified or amidated, or an acyl group;  $R^4$  is a hydrocarbon group which may be substituted; and  $R^2$  and  $R^1$  or  $R^4$ , and  $R^3$  and  $R^4$  may be respectively bonded to each other to form a ring which may be substituted);  $R^6$  and  $R^1$ ,  $R^2$ ,  $R^3$  or  $R^4$  may be bonded to each other to form a ring which may be substituted; and  $a$  is 0, 1 or 2, or a salt thereof.

2. (ORIGINAL) A prodrug of the compound according to claim 1.


3. (ORIGINAL) The compound according to claim 1, wherein  $R$  is an aryl group which may be substituted with a substituent selected from a halogen atom,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl, amino which may be substituted, nitro, cyano, amidino which may be substituted, and carboxyl which may be esterified or amidated.

4. (ORIGINAL) The compound according to claim 1, wherein  $R$  is a heterocyclic group which may be substituted with a substituent selected from a halogen atom,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl, amino which may be substituted, nitro, cyano, amidino which may be substituted, and carboxyl which may be esterified or amidated.

5. (ORIGINAL) The compound according to claim 1, wherein R is naphthyl which may be substituted with a halogen atom.
6. (ORIGINAL) The compound according to claim 1, wherein X is a bond, X' is a bond, Y is C<sub>1-3</sub> alkylene which may be substituted, and Y' is -C(=O)-.
7. (ORIGINAL) The compound according to claim 6, wherein Y is C<sub>1-3</sub> alkylene substituted with a hydroxyl group.
8. (ORIGINAL) The compound according to claim 1, wherein Z<sup>1</sup> and Z<sup>2</sup> are each a bond, and Z<sup>3</sup> is C<sub>1-3</sub> alkylene which may be substituted.
9. (ORIGINAL) The compound according to claim 1, wherein ring A is a piperazine ring which may be substituted or a piperidine ring which may be substituted.
10. (ORIGINAL) The compound according to claim 1, wherein ring A is a ring represented by the formula:



wherein ring A' may be further substituted,  
or the formula:




wherein ring A'' may be further substituted.

11. (ORIGINAL) The compound according to claim 1, wherein R<sup>5</sup> is a hydrogen atom.
12. (ORIGINAL) The compound according to claim 1, wherein a is 2.

13. (ORIGINAL) A compound selected from the group consisting of N-(4-((4-(3-((6-chloro-2-naphthyl)sulfonyl)propanoyl)-1-piperazinyl)methyl)-3-methyl-1,3-thiazol-2(3H)-ylidene)-N-methylamine, 4-((4-(3-((6-chloro-2-naphthyl)sulfonyl)propanoyl)-1-piperazinyl)methyl)-3-methyl-1,3-thiazol-2(3H)-imine, N-(5-((1-(3-((6-chloro-2-naphthyl)sulfonyl)propanoyl)-4-piperidinyl)methyl)-3-methyl-1,3-thiazol-2(3H)-ylidene)-N-methylamine, 5-(1-(3-((6-chloro-2-naphthyl)sulfonyl)propanoyl)-4-piperidinyl)-3-methyl-1,3-thiazol-2(3H)-imine, and 2-(2-((1-(3-((6-chloro-2-naphthyl)sulfonyl)propanoyl)-4-piperidinyl)imino)-1,3-thiazol-3(2H)-yl)ethanol, or a salt thereof or a prodrug thereof.

14. (CURRENTLY AMENDED) A compound represented by Formula (II') ~~(II)~~:



wherein  $P^0$  is a hydrogen atom, or a protective group for imino group; and the other symbols have the same meanings as defined in claim 1,

or a salt thereof.

15. (ORIGINAL) A pharmaceutical composition comprising the compound according to claim 1 or 2.

16. (ORIGINAL) The pharmaceutical composition according to claim 15, which is an anticoagulant.

17. (ORIGINAL) The pharmaceutical composition according to claim 15, which is an activated blood coagulation factor X inhibitor.

18. (ORIGINAL) The pharmaceutical composition according to claim 15, which is a medicament for preventing or treating myocardial infarction, cerebral infarction, deep vein thrombosis, pulmonary thromboembolism or atherosclerotic obliterans.

19. (ORIGINAL) The pharmaceutical composition according to claim 15, which is a medicament for preventing or treating economy-class syndrome, thromboembolism during and post operation, or the secondary onset of deep vein thrombosis.

20. (ORIGINAL) A method for inhibiting blood coagulation in a mammal, which comprises administering an effective amount of the compound according to claim 1 or a prodrug thereof to a mammal.

21. (ORIGINAL) The method for inhibiting an activated blood coagulation factor X in a mammal, which comprises administering an effective amount of the compound according to claim 1 or a prodrug thereof to a mammal.

22. (ORIGINAL) The method for preventing or treating myocardial infarction, cerebral infarction, deep vein thrombosis, pulmonary thromboembolism or atherosclerotic obliterans in a mammal, which comprises administering an effective amount of the compound according to claim 1 or a prodrug thereof to a mammal.

23. (ORIGINAL) Use of the compound according to claim 1 or a prodrug thereof, for manufacturing a medicament for inhibiting blood coagulation.

24. (ORIGINAL) Use of the compound according to claim 1 or a prodrug thereof, for manufacturing a medicament for inhibiting an activated blood coagulation factor X.

25. (ORIGINAL) Use of the compound according to claim 1 or a prodrug thereof, for manufacturing a medicament for preventing or treating myocardial infarction, cerebral infarction, deep vein thrombosis, pulmonary thromboembolism or atherosclerotic obliterans.